# Evaluation of the Effectiveness and Impact of Nirsevimab Administered as Routine Immunization

> **NCT06180993** · — · RECRUITING · sponsor: **Federico Martinón Torres** · enrollment: 42000 (estimated)

## Conditions studied

- RSV Infection

## Interventions

- **BIOLOGICAL:** Nirsevimab

## Key facts

- **NCT ID:** NCT06180993
- **Lead sponsor:** Federico Martinón Torres
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-25
- **Primary completion:** 2026-03-31
- **Final completion:** 2026-10-31
- **Target enrollment:** 42000 (ESTIMATED)
- **Last updated:** 2023-12-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06180993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06180993, "Evaluation of the Effectiveness and Impact of Nirsevimab Administered as Routine Immunization". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT06180993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*